Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
0.0001
0.0000
(0.00%)
At close: February 24 at 10:41:18 AM EST
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
82.0490
82.0490
200.7490
277.0870
Cost of Revenue
23.7670
23.7670
52.0300
64.1170
Gross Profit
58.2820
58.2820
148.7190
212.9700
Operating Expense
1,778.7660
1,778.7660
2,284.5770
2,613.2110
Operating Income
-1,720.4840
-1,720.4840
-2,135.8580
-2,400.2410
Net Non Operating Interest Income Expense
-689.9770
-689.9770
-1,000.1480
-488.3690
Other Income Expense
-447.4820
-447.4820
-151.4100
-1.8830
Pretax Income
-2,857.9430
-2,857.9430
-3,287.4160
-2,890.4930
Net Income Common Stockholders
-2,857.9430
-2,857.9430
-3,287.4160
-2,890.4930
Diluted NI Available to Com Stockholders
-2,857.9430
-2,857.9430
-3,287.4160
-2,890.4930
Basic EPS
-0.00
--
-0.01
-0.01
Diluted EPS
-0.00
--
-0.01
-0.01
Basic Average Shares
591,558.2880
--
460,794.4910
429,291.0110
Diluted Average Shares
591,558.2880
--
460,794.4910
429,291.0110
Total Operating Income as Reported
-1,720.4840
-1,720.4840
-2,135.8580
-2,400.2410
Total Expenses
1,802.5330
1,802.5330
2,336.6070
2,677.3280
Net Income from Continuing & Discontinued Operation
-2,857.9430
-2,857.9430
-3,287.4160
-2,890.4930
Normalized Income
-2,410.4490
-2,410.4490
-3,287.4160
-2,911.9670
Interest Expense
689.9770
689.9770
1,000.1480
488.3690
Net Interest Income
-689.9770
-689.9770
-1,000.1480
-488.3690
EBIT
-2,167.9660
-2,167.9660
-2,287.2680
-2,402.1240
EBITDA
-2,167.9660
-2,167.9660
-2,287.2680
-2,402.1240
Reconciled Cost of Revenue
23.7670
23.7670
52.0300
64.1170
Net Income from Continuing Operation Net Minority Interest
-2,857.9430
-2,857.9430
-3,287.4160
-2,890.4930
Total Unusual Items Excluding Goodwill
-447.4940
-447.4940
--
21.4740
Total Unusual Items
-447.4940
-447.4940
--
21.4740
Normalized EBITDA
-1,720.4720
-1,720.4720
-2,287.2680
-2,423.5980
12/31/2020 - 2/19/2008
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ISCO International Stem Cell Corporation
0.1200
0.00%
TCON TRACON Pharmaceuticals, Inc.
0.0322
0.00%
HALB Halberd Corporation
0.0025
+4.17%
INKT MiNK Therapeutics, Inc.
10.65
+3.40%
AGEN Agenus Inc.
3.1600
-4.82%
BLRX BioLineRx Ltd.
3.6700
+2.23%
CELZ Creative Medical Technology Holdings, Inc.
4.9200
-8.89%
FATE Fate Therapeutics, Inc.
1.3600
-4.23%
VRNA Verona Pharma plc
65.60
-3.47%
NTLA Intellia Therapeutics, Inc.
11.51
-5.42%